These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 12320455)

  • 1. Oral contraceptives and venous thromboembolism: consensus conference statement.
    Dialogues in Contraception Consensus Conference (1995: Chicago)
    Dialogues Contracept; 1996; ():1-8. PubMed ID: 12320455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology of venous thromboembolic disease and OC use.
    Ory HW
    Dialogues Contracept; 1996; 5(1):4-7, 10. PubMed ID: 12347722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venous thromboembolism and desogestrel- or gestodene-containing combination oral contraceptives: what are the facts?
    Contracept Rep; 1996 Apr; 7(1):3-6. PubMed ID: 12320047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral contraceptive pills and the risk of venous thromboembolism.
    Prog Hum Reprod Res; 1996; (39):2-3. PubMed ID: 12292198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel.
    Jick SS; Kaye JA; Russmann S; Jick H
    Contraception; 2006 Jun; 73(6):566-70. PubMed ID: 16730485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A perspective on the concept of "risk".
    Westhoff CL
    Dialogues Contracept; 1996; 5(1):8-9. PubMed ID: 12347723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coagulation and thrombosis with OC use: physiology and clinical relevance.
    Comp PC
    Dialogues Contracept; 1996; 5(1):1-3. PubMed ID: 12347721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
    Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
    Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. German court lifts OC prescription ban.
    Contracept Technol Update; 1998 Mar; 19(3):41-2. PubMed ID: 12293274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.
    Jick H; Jick SS; Gurewich V; Myers MW; Vasilakis C
    Lancet; 1995 Dec; 346(8990):1589-93. PubMed ID: 7500750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of combined low-dose oral contraceptives on blood viscosity and haematocrit.
    Ishak R; Loh Chooi Khim
    Malays J Reprod Health; 1991 Jun; 9(1):5-8. PubMed ID: 12317443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen dose in oral contraceptives: FDA committee examines safety and utility of 50 mcg estrogen OCs.
    Contracept Rep; 1994 Mar; 5(1):10-3. PubMed ID: 12287738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of oral contraceptives containing gestodene and risk of venous thromboembolism: outlook 10 years after the third-generation "pill scare".
    Heinemann LA; Dinger JC; Assmann A; Minh TD
    Contraception; 2010 May; 81(5):401-7. PubMed ID: 20399946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Another pill scare -- should we audit its impact?
    Bromham DR
    Audit Unit News; 1996 Jan; 1(4):2-3. PubMed ID: 12346948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral contraceptive use and venous thromboembolism: a consideration of the impact of bias and confounding factors on epidemiological studies.
    Rekers H; Norpoth T; Michaels MA
    Eur J Contracept Reprod Health Care; 1996; 1(1):21-30. PubMed ID: 9678134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen and progestin components of oral contraceptives: relationship to vascular disease.
    Carr BR; Ory H
    Contraception; 1997 May; 55(5):267-72. PubMed ID: 9220222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral contraceptive risks: a realistic appraisal.
    Bressler R; Durand JL
    Drug Ther (NY); 1979 Oct; 9(10):81-95. PubMed ID: 12279276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Combined contraceptives and cardiovascular risk].
    Belaisch J; Hommais-loufrani B
    Contracept Fertil Sex (Paris); 1987 Dec; 15(12 Suppl):1-8. PubMed ID: 12315199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Warnings on venous thromboembolism risks may have been premature. New data may lead to change in use of third-generation OCs.
    Contracept Technol Update; 1997 Dec; 18(12):145-8. PubMed ID: 12348219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2 methods for prescribing third-generation OCs.
    Contracept Technol Update; 1997 Dec; 18(12):148-9. PubMed ID: 12348220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.